SCHEMBL5233604

SCHEMBL5233604

CCOc1cc(S(=O)(=O)Cl)ccc1-c1nc2c(C)nn(-c3ccccc3)c2c(=O)[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 11/20 0.57
PDE1A P54750 5/20 0.46
PDE1B Q01064 5/20 0.46
PDE1C Q14123 5/20 0.46
KDM4E B2RXH2 2/20 0.46
KMT2A Q03164 2/20 0.46
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 1/20 0.46
HPGD P15428 1/20 0.46
NPSR1 Q6W5P4 2/20 0.44
MAPT P10636 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
HIF1A Q16665 1/20 0.43
MCOLN3 Q8TDD5 1/20 0.43
GUSB P08236 1/20 0.41
PDE2A O00408 1/20 0.41
ABCC4 O15439 1/20 0.41
ABCC5 O15440 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5230059 0.91 PDE7A (0.47) PDE5ALMNAPDE4DPDE7A
SCHEMBL5230167 0.85 PDE5A (0.77) PDE5APDE1APDE1BPDE1CKDM4E
SCHEMBL5232435 0.85 PDE5A (0.61) PDE5APDE1APDE1BPDE1CKDM4E
SCHEMBL5228498 0.84 PDE5A (0.51) PDE5APDE1APDE1BPDE1CPDE2A
SCHEMBL5233598 0.82 PDE7A (0.61) PDE5APDE1APDE1BPDE1CPDE4D
SCHEMBL5234570 0.81 PDE7A (0.47) PDE5AKDM4EALDH1A1HPGDNPSR1
SCHEMBL845 0.80 PDE5A (0.68) PDE5APDE1APDE1BPDE1CKDM4E
SCHEMBL5228298 0.80 PDE5A (0.55) PDE5APDE1APDE1BPDE1CKDM4E
SCHEMBL5233408 0.80 PDE5A (0.55) PDE5APDE1APDE1BPDE1CKDM4E
SCHEMBL5229885 0.80 PDE5A (0.58) PDE5APDE1APDE1BPDE1CKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1454897-B1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY ASUBIO PHARMA CO LTD (JP) 2007-10-10 EP disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 US disclosed
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action OMEROS CORPORATION 2005-07-07 US disclosed
EP-1454897-A1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY Daiichi Suntory Pharma Co., Ltd. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action PDE7B, PDE3B, PDE3A PDE5A 8/4885PDE1A 17/4885PDE1B 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.